GI Pipeline Could Make for a Larger Market if Successful
51% of the overall gastrointestinal therapeutic pipeline is in Phase II to Phase III development, of which 19 molecules are indicated for the treatment of Irritable Bowel Syndrome, 48 for ulcerative colitis, and 41 for Chron?s Disease.
According to GBI Research, 51% of the overall gastrointestinal therapeutic pipeline is in Phase II to Phase III development, of which 19 molecules are indicated for the treatment of Irritable Bowel Syndrome, 48 for ulcerative colitis, and 41 for Chron’s Disease. These pipeline drugs, coupled with the increasing prevalence of GI diseases could help stabilize what the research says could be a declining market.
The business intelligence firm is calling for a decline of the GI therapeutics market, from $6.8B in 2012 to a $6.6B in 2019. This is based on the patent expiry of both Humira and Remicade, and entries of generics and biosimilars impacting sales.
One drug from Takeda, vedolizumab will enter two new Phase III trials in Japan. In addition, Takeda has submitted a Marketing Authorization Application (MAA) to the EMA in March 2013, as well as a Biologics License Application (BLA) to the FDA in June 2013, for the treatment of moderately to severely active ulcerative colitis or Crohn’s disease. Inflectra or infliximab, the biosimilar of Remicade, is the first monoclonal antibody to be approved through the EMAs biosimilars regulatory pathway and will be marketed by Hospira and available in the EU in February 2015. The drug is indicated for the treatment of inflammatory conditions including rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis psoriatic arthritis and psoriasis.
The full release is available
here
.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
